Plain-English translation of NCT05665361 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether palbociclib and , two medications that work in different ways, can be effective when combined to treat advanced kidney cancer. Palbociclib works by slowing down cancer cell growth, while helps your immune system recognize and fight cancer cells. Researchers believe these two medications may work better together than either one alone.
Most patients with advanced kidney cancer are first treated with immune therapies or drugs that target blood vessel growth, but many eventually stop responding to these treatments. This trial exists because there is a real need for new treatment options for patients whose cancer has progressed, and early research suggests that combining these two medications might offer hope.
You likely qualify if…
You likely don't qualify if…
In this trial, you would take the two medications together—one as an oral pill daily and one as an injection under the skin once a month. The trial has two phases: in Phase I, researchers test different doses to find the safest combination; in Phase II, participants receive the dose that worked best. You would have regular visits to the clinic for lab work, imaging scans, and check-ins with your medical team to monitor how you are responding and manage any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States